| 新型抗凝血药物的研究进展 |
| |
| 引用本文： | 武云强张威王琰龙铟郝晓柯刘家云.新型抗凝血药物的研究进展[J].现代生物医学进展,2012,12(16):3198-3200. |
| |
| 作者姓名： | 武云强张威王琰龙铟郝晓柯刘家云 |
| |
| 作者单位： | 第四军医大学西京医院全军临床检验医学中心 陕西西安710032 |
| |
| 基金项目： | 国家“重大新药创制”科技重大专项(2009ZX09103-669);国家自然科学基金项目(81073095) |
| |
| 摘 要： | 当前临床上主要的抗凝血药物如肝素、华法林及重组水蛭素等存在出血,需要实验室监测,药物半衰期短等不足。以pegmusirudin、HD1-22、flovagatran、otamixaban、RB-006、EP217609等为代表的新型抗凝血药物克服了现有抗凝剂的诸多不足,为抗凝和溶栓治疗提供了更多选择。本文就相关研究及进展进行综述。
|
| 关 键 词： | 抗凝血药物 凝血酶抑制剂 水蛭素 凝血因子抑制剂 |
Research Progress of Novel Anticoagulants |
| |
| WU Yun-qiang,ZHANG Wei,WANG Yan,LONG Yin,HAO Xiao-ke,LIU Jia-yun.Research Progress of Novel Anticoagulants[J].Progress in Modern Biomedicine,2012,12(16):3198-3200. |
| |
| Authors: | WU Yun-qiang ZHANG Wei WANG Yan LONG Yin HAO Xiao-ke LIU Jia-yun |
| |
| Institution: | (Center for Clinical Laboratory Medicine,Xijing Hospital,Fourth Military Medical University,Xi’an Shaanxi 710032,China) |
| |
| Abstract: | The current anticoagulants available to clinicians such as heparin,warfarin and recombinant hirudins(i.e.bivalirudin,desirudin,lepirudin) have some drawbacks including heparin-induced bleeding,need of laboratory monitoring of warfarin and short half-life of hirudin in vivo.Novel parenteral anticoagulants in development representative by pegmusirudin,HD1-22,flovagatran,otamixaban,RB-006,EP217609 overcome the shortcoming of anticoagulants available now.They provide more alternatives to anticoag-ulant therapy and thrombolytic therapy.The review addresses the advance of novel anticoagulants in development. |
| |
| Keywords: | Anticoagulant drugs Thrombin inhibitor Hirudin Blood coagulation factor inhibitor |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
| 点击此处可从《现代生物医学进展》浏览原始摘要信息 |
| 点击此处可从《现代生物医学进展》下载免费的PDF全文 |
|
